Anocca

Anocca is a Swedish clinical-stage biotechnology company developing advanced T-cell immunotherapies. Founded in 2014, it has built a deep tech platform combining novel biotechnologies, processes and infrastructure to analyse T-cell biology at scale, together with an integrated software ecosystem. Its primary focus is engineering T-cell receptor engineered T-cell therapies (TCR-T) for untreatable cancers, and it develops and manufactures libraries of TCR-T cell therapies at in-house facilities in Sweden. The company is more than 120 scientists, software developers, engineers, manufacturing and quality specialists, and support and business personnel, with a team drawn from over 35 nations.

Anocca was founded in 2014 to build the biotechnologies, processes and infrastructure needed to decode T-cell immunity, with the ambition to build new forms of T-cell immunotherapies. Over the following decade the company invented, refined and deployed technologies and infrastructure into a deep tech platform to analyse T-cell biology at scale. It now focuses on the development and manufacturing of libraries of TCR-T cell therapies for the hardest to treat cancers, working out of state-of-the-art facilities in Sweden. On 11 June 2026, Anocca announced the successful dosing of the first patients across multiple clinical sites with ANOC-001, a TCR-T therapy targeting KRAS G12V mutations in an aggressive form of pancreatic cancer; ANOC-001 is the first product to enter the company's VIDAR-1 clinical programme focused on pancreatic ductal adenocarcinoma (PDAC).

Precision T-cell immunotherapies for the hardest to treat cancers, built on a deep tech platform for decoding T-cell immunity.

• ANOC-001

  A novel T cell receptor-modified T cell therapy (TCR-T) targeting KRAS G12V mutations in an aggressive form of pancreatic cancer; the first product to enter Anocca's VIDAR-1 clinical programme.

• Unconfirmed

  Reported2021.07.22

  Anocca closes $47 million Series B financing[6]Anocca完成4,700万美元B轮融资finanznachrichten.de

  Anocca announced the closing of a USD 47 million Series B financing to advance its cellular biology platform and progress its TCR-T therapies into clinical trials. The financing was led by advisor Danske Bank and included new and existing investors.

Read more

1. 1Engineered Immunity by Anoccaanocca.com
2. 2About | Anoccaanocca.com
3. 3News | Anoccaanocca.com
4. 4Events | Anoccaanocca.com
5. 5Anocca (Sweden)wikidata.org
6. 6Anocca完成4,700万美元B轮融资finanznachrichten.de